Physicians'​ Choice Infusion Pharmacy’s Post

Research indicates that tirzepatide is more effective than semaglutide in promoting weight loss among participants. This promising result could mark a significant advancement in obesity treatment, offering new hope for those struggling with weight management. #Healthcare #WeightLoss #ClinicalResearch #Innovation https://lnkd.in/gZfkRdTe

While a diagnosis often distills the essence of a diseased state, targeted treatments rarely offer long-term benefits for patients when they focus too narrowly on a single condition. This aggressively restrictive approach can often lead to suboptimal outcomes. A prime example is the use of GLP-1 agonists, such as semaglutide, in managing obesity and diabetes. While highly effective, these treatments can lead to lean muscle loss. Recent studies suggest that this muscle loss is not significant and is comparable to age-related muscle decline. However, much of the focus has shifted towards developing new therapies to address this, rather than exploring more immediate, complementary strategies—like the role of a high-protein diet. A high-protein diet, when combined with GLP-1 agonists, could not only help protect muscle mass but also enhance satiety, acting synergistically to improve outcomes. This approach seems like a missed opportunity in current research and clinical practice. As stakeholders, we may have an opportunity to embrace a more holistic approach—what I like to call “tapestry weaving”—where GLP-1 agonists are combined with targeted diet and lifestyle changes. And where needed, future therapies can be introduced to protect muscle mass or even enhance basal metabolic rate (BMR). All the different tools to be woven together differently for each patient to create a tapestry of treatment unique to that patient to lead to the best outcomes! Serendipitously, one thing is for sure. The more tools we have at our disposal, the more we understand that "one size fits all" rarely works in healthcare. Thankfully, we may have the right solutions too!! #semaglutide #GLP1 #Ozempic #obesity #diabesity #diabetes #musclemass #tapestryweaving

💊💪 Weight-loss drug found to slow down the aging process #Semaglutide – known by brands names #Ozempic and #Wegovy is poised to revolutionise healthcare by slowing down the ageing process and by allowing people to live for longer and in better health, with those taking the medication found dying at a lower rate from all causes. The studies were produced from the Select trial in the US, which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes. They received semaglutide or a placebo and were tracked for more than three years. A total of 833 participants died during the study, of which 58% were related to cardiovascular causes and 42% from others, with infections being the most common cause of death in this latter group. Crucially, those who took semaglutide were less likely to die of infections than those in the placebo group while it also consistently reduced the risk of adverse cardiovascular outcomes, it was found. Ben Scirica, a Harvard professor and the lead author of one of the studies has commented that the robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and the findings reinforce that overweight and obesity increases the risk of death due to many etiologies which can be modified with therapies like semaglutide. Read in full ⬇️ https://lnkd.in/e8jxusPu

🚀 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🌟 SUN PHARMA's GL0034 (𝐔𝐭𝐫𝐞𝐠𝐥𝐮𝐭𝐢𝐝𝐞) showcased promising results at the 84th Scientific Sessions of the American Diabetes Association in Orlando! 🏥 𝐇𝐞𝐫𝐞'𝐬 𝐰𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐞𝐝: 🔹 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐌𝐞𝐚𝐧𝐢𝐧𝐠𝐟𝐮𝐥 𝐖𝐞𝐢𝐠𝐡𝐭 𝐋𝐨𝐬𝐬: Significant reduction in body weight within just 4 weeks. 🔹 𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭𝐬: Enhanced glucometabolic parameters and insulin sensitivity. 🔹 𝐋𝐢𝐩𝐢𝐝-𝐋𝐨𝐰𝐞𝐫𝐢𝐧𝐠 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Noticeable decreases in triglycerides and cholesterol levels. 🔹 𝐖𝐞𝐥𝐥-𝐭𝐨𝐥𝐞𝐫𝐚𝐭𝐞𝐝: No treatment-related discontinuations, with mild gastrointestinal side effects. 👥 𝑺𝒕𝒖𝒅𝒚 𝑫𝒆𝒕𝒂𝒊𝒍𝒔: 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐧𝐭𝐬: 24 healthy, obese males aged 18-40. 𝐃𝐨𝐬𝐚𝐠𝐞: Weekly doses of GL0034 in varying amounts. This innovative GLP-1 receptor agonist offers a promising future for obesity management and related comorbidities. 🌐 Let's continue to pave the way for better health! 💪 #SunPharma #ObesityTreatment #ClinicalResearch #HealthInnovation

Zone.Health presented research on a hybrid weight loss program at the American Diabetes Association. This study explored the effectiveness of combining GLP-1 medications with a multi-dimensional lifestyle intervention for obesity and prediabetes management. GLP-1 medications are effective for weight loss but often do not emphasize long-term behavioral changes, which can lead to weight regain and limit their overall effectiveness. This shortfall is particularly critical for prediabetes patients, who need sustained interventions to prevent the progression to type 2 diabetes. Zone.Health's Hybrid Approach: This retrospective study evaluated a 𝟲-𝗺𝗼𝗻𝘁𝗵 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 offered by Zone.Health. The program included: ⏺ GLP-1 medications: Tirzepatide, semaglutide, or liraglutide were prescribed. ⏺ Multi-dimensional lifestyle modification: Delivered digitally via an app, this included: ✔Accountability coaching ✔Food logging ✔Continuous glucose monitoring (CGM) ✔Personal training support 𝗥𝗲𝘀𝘂𝗹𝘁𝘀: ◘ Overall, participants achieved a significant 7.89 kg (8.24%) weight loss after 3 months (p < 0.001). ◘ This translated to reduced BMI, fat mass, and improved cholesterol levels. ◘ Prediabetic patients (n=33) experienced even greater benefits: - ⁠81% of prediabetic patients reversed their condition to healthy clinical profile • HbA1c reduction of 0.46% (p < 0.001) from 5.85 ± 0.18 to 5.39 ± 0.27 - Substantial weight loss (-6.85 kg, -6.8%) (p < 0.001) and improved lipid profile Read more: https://lnkd.in/d6QsjP5H #adass24 #diabetesresearch #zonehealth #glucare #GLP1 #weightloss #prediabetes Ihsan Almarzooqi - Ali Hashemi - Hala Zakaria, MSc, RD I حلا زكريا

We asked Novo Nordisk to analyze the #Wegovy STEP trials to see how medications for hyperlipidemia and hypertension changed with #weightloss and partnered with them to report out results: https://lnkd.in/encTdrPd In adults with #obesity (STEP 1, 3, 6, 8): 👉 34.2% on sema 2.4 ⬇️ or 🛑'd their antihypertensive, vs 13.8% on placebo 👉 14.1% ⬇️ or 🛑'd their lipid-lowering agent, vs 8.4% on placebo In adults with #obesity and #diabetes (STEP 2, 6): 👉24.5% on sema 2.4 ⬇️ or 🛑'd their antihypertensive vs 13.0% on placebo 👉 14.7% ⬇️ or 🛑'd their lipid-lowering agent, vs 6.3% on placebo 🔥 Significant weight loss allows for and should prompt de-escalation of therapies for co-morbid conditions

Can lifestyle changes be prescribed to eliminate type 2 diabetes? Researchers from Aarhus University, Steno Diabetes Center Aarhus, and Aarhus Universitetshospital is about to launch Denmark's largest-ever project aimed at reversing type 2 diabetes through tailored lifestyle interventions. With over 100 million DKK in funding from the Novo Nordisk Foundation, this ambitious study, led by Clinical Professor Søren Gregersen, will uncover, whether personalized plans for weight loss, dietary changes, and exercise can completely eliminate type 2 diabetes. The project is set to involve 1,500 participants recently diagnosed with diabetes, focusing on how customized plans can transform diabetes management. The goal? To create scalable solutions that reduce the societal and individual burden of diabetes. Could this project set a new standard in diabetes care, pushing us closer to a future where type 2 diabetes is not just manageable but reversible? 📸: Steno Diabetes Center Aarhus

👨⚕️ World Hypertension Day 👩⚕️ 📢 It is crucial to understand why managing polypharmacy in hypertension requires top-tier expertise. Polypharmacy, the concurrent use of multiple medications, presents unique challenges in hypertension management that demand the utmost proficiency and precision. 🔀 Firstly, hypertension is a complex condition often requiring multifaceted treatment approaches. Individuals with hypertension commonly have comorbidities such as diabetes, heart disease, or renal impairment, necessitating the use of multiple medications. Managing these medications concurrently requires a deep understanding of their pharmacological interactions, potential side effects, and the delicate balance needed to achieve optimal blood pressure control while minimizing adverse outcomes. 📈 Moreover, the consequences of poorly managed polypharmacy in hypertension can be severe. Suboptimal medication regimens may lead to treatment non-adherence, drug interactions, or exacerbation of underlying conditions, ultimately compromising patient health and increasing the risk of cardiovascular events such as heart attacks or strokes. 💊 Furthermore, the landscape of hypertension management is constantly evolving, with new drugs, guidelines, and treatment strategies emerging regularly. Staying abreast of these developments and integrating them effectively into patient care requires the expertise and commitment of top-tier healthcare professionals. ⭐ OptimisHealth offers a distinguished solution to the intricate challenge of managing polypharmacy. At Optimis Health, we pride ourselves on our commitment to excellence and innovation in healthcare delivery, ensuring optimal patient outcomes and satisfaction. 🌟 By investing in top experts in hypertension management, our healthcare service can ensure the highest quality of care for our patients, optimizing outcomes and upholding our commitment to excellence in healthcare delivery. 👨🏫 At OptimisHealth, we recognize the paramount importance of patient-centered care. Our philosophy revolves around empowering patients through education and engagement, fostering a deeper understanding of their medications and treatment plans. By involving patients in shared decision-making processes, we cultivate a sense of ownership and accountability, ultimately enhancing medication adherence and mitigating the risk of adverse effects. 👨👧👧 Our dedication to advancing healthcare standards sets us apart as leaders in the industry, delivering unparalleled value and outcomes for our patients. 🤝 Follow us OptimisHealth to see how we can assist you and your family on their health journeys. #WorldHypertensionDay #Hypertension #Awareness #Polypharmacy #Health #Healthjourney #Topexperts #Care #PrivateHealthcare

Patients with persistent hypertension despite multiple medications are at high risk for adverse cardiovascular events and are more likely to have secondary causes of hypertension as the implicating factor. RISK FACTORS INCLUDE: - Suboptimal therapy - Lifestyle and diet - Medications -Extracellular volume expansion - Secondary causes of hypertension (Primary aldosteronism, Renal artery stenosis, Chronic Kidney disease, ASA) Consider medical history evaluation, Laboratory evaluation, Physical examination and non-invasive imaging of renal artery stenosis

All three #GLP-1s — #semaglutide, #tirzepatide, and liraglutide — offer significant benefits in managing type 2 diabetes and #weightloss but differ in their administration schedules, efficacy, and additional benefits. We are breaking down how they differ in our latest insight article.